Tickers

1. Composite Trajectory Verdict

For a pre-revenue clinical-stage biopharmaceutical company, the cash flow statement and balance sheet (liquidity and runway) carry the most weight because they determine the entity's ability to continue operations and fund development; the income statement primarily reflects the pace of cash consumption.

Composite Trajectory: Mixed

The income statement shows a consistent year-over-year reduction in net losses across all comparable periods (FY 2025 vs FY 2024, Q2 2026 vs Q2 2025, Q1 2026 vs Q1 2025, YTD Q2 2026 vs YTD Q2 2025), driven by declining R&D spend as the Phase 2 mPDAC trial winds down. However, the cash flow and balance sheet trajectories are deteriorating sharply: cash fell from $13.2M (Dec 2025) to $4.4M (Jun 2026), working capital dropped from $7.9M to $0.9M, and stockholders' equity collapsed from $7.9M to $1.0M over the same six months. Financing inflows have nearly ceased ($0.7M in H1 2026 vs $6.6M in H1 2025), and the company explicitly states substantial doubt about its ability to continue as a going concern with cash only projected to last into September 2026.

2. Red Flags

• Going concern doubt explicitly disclosed in FY 2025 10-K, Q1 2026 10-Q, and Q2 2026 10-Q, with management estimating cash runway only to July 2026 (10-K) / September 2026 (Q2 2026) without additional capital (10-K FY2025, Liquidity; 10-Q Q2 2026, Liquidity)
• Cash position declined 66% in six months: $13,159,423 (Dec 31, 2025) → $8,134,004 (Mar 31, 2026) → $4,425,841 (Jun 30, 2026) (10-K FY2025 Balance Sheet; 10-Q Q1 2026 Balance Sheet; 10-Q Q2 2026 Balance Sheet)
• Working capital eroded 88% in six months: $7,936,503 (Dec 31, 2025) → $3,797,551 (Mar 31, 2026) → $942,745 (Jun 30, 2026) (10-K FY2025 MD&A; 10-Q Q1 2026 MD&A; 10-Q Q2 2026 MD&A)
• Stockholders' equity dropped 87% in six months: $7,924,003 (Dec 31, 2025) → $3,784,398 (Mar 31, 2026) → $989,152 (Jun 30, 2026) (10-K FY2025 Balance Sheet; 10-Q Q1 2026 Balance Sheet; 10-Q Q2 2026 Balance Sheet)
• Financing cash inflows collapsed: $6,643,535 in YTD Q2 2025 vs $688,868 in YTD Q2 2026 (10-Q Q2 2026 Cash Flows)
• ATM facility largely unused: $100M capacity with only $1,249,591 net proceeds in H1 2026 at weighted-average $2.66/share (10-Q Q2 2026, Note 1)
• Accumulated deficit exceeds $165M with zero revenue: $165,100,085 as of Jun 30, 2026 (10-Q Q2 2026 Balance Sheet)
• UIC license payable triggers: $404,991 principal plus accruing interest becomes due upon events including $85M equity financing or $200M cumulative financing (10-Q Q2 2026, Note 5)

3. Earnings Assessment (Income Statement)

Earnings Trajectory: Improving

Net losses have decreased year-over-year in every comparable period provided: FY 2025 net loss of $22,227,852 vs FY 2024 $27,285,328 (10-K FY2025, Statements of Operations); Q2 2026 net loss $4,866,635 vs Q2 2025 $5,949,405 (10-Q Q2 2026, Statements of Operations); Q1 2026 net loss $5,625,749 vs Q1 2025 $6,317,024 (10-Q Q1 2026, Statements of Operations); YTD Q2 2026 net loss $10,492,384 vs YTD Q2 2025 $12,266,429 (10-Q Q2 2026, Statements of Operations). Total operating expenses declined in each comparable period, driven by lower external clinical study expenses as the Phase 2 mPDAC trial (Actuate-1801 Part 3B) winds down, partially offset by rising G&A expenses from increased stock-based compensation and public company costs.

4. Cash Generation Assessment (Statement of Cash Flows)

Cash Trajectory: Deteriorating

Operating cash burn remains high and slightly increased on a comparable YTD basis: $9,422,450 used in YTD Q2 2026 vs $8,792,501 in YTD Q2 2025 (10-Q Q2 2026, Cash Flows). More critically, financing cash inflows have nearly vanished: $688,868 in YTD Q2 2026 vs $6,643,535 in YTD Q2 2025 (10-Q Q2 2026, Cash Flows). The net change in cash swung from -$2,148,966 (YTD Q2 2025) to -$8,733,582 (YTD Q2 2026). Quarterly operating cash burn was $5,017,327 in Q1 2026 vs $4,618,740 in Q1 2025, with financing turning negative in both Q1 periods (-$8,092 vs -$133,477). The company is relying on an ATM facility with $98.7M remaining capacity but minimal utilization to date.

5. Balance Sheet Assessment

Balance Sheet Trajectory: Deteriorating

Liquidity and equity positions have deteriorated rapidly over the first half of 2026. Cash and cash equivalents fell from $13,159,423 (Dec 31, 2025) to $4,425,841 (Jun 30, 2026) (10-K FY2025 Balance Sheet; 10-Q Q2 2026 Balance Sheet). Total current assets dropped from $13,643,419 to $4,747,941, while current liabilities decreased more slowly from $5,706,916 to $3,805,196, compressing working capital from $7,936,503 to $942,745 (10-K FY2025 MD&A; 10-Q Q2 2026 MD&A). Total stockholders' equity declined from $7,924,003 to $989,152, while accumulated deficit grew from $154,607,701 to $165,100,085 (10-K FY2025 Balance Sheet; 10-Q Q2 2026 Balance Sheet). Total liabilities decreased from $6,111,907 to $4,210,187, primarily from paying down accounts payable and accrued clinical study costs.

6. Data Gaps

• Q3 2025 and Q4 2025 quarterly income statements, cash flows, and balance sheets (only annual FY2025 and YTD Q2 2026, Q1 2026, Q2 2025 are provided)
• Standalone Q2 2026 and Q3 2025 quarterly figures (only YTD and Q1/Q2 comparatives available)
• Detailed breakdown of "Other accrued expenses" components beyond clinical study costs
• Terms and draw schedule for the Committed Equity Facility beyond the 3% discount to VWAP
• Specific triggers and timing for UIC license payable repayment beyond the disclosed clauses
• Cash flow statement for FY2024 in the 10-K (only summary provided in MD&A, full statement not in XBRL excerpt)